RHEI Pharmaceuticals NV of Belgium has optioned the China rights for Invisicare from Skinvisible, Inc. Invisicare is a patented polymer delivery system, designed to be combined with topical drug products, which extends the time that active pharmaceutical ingredients remain on the skin, resisting both wash off and perspiration. RHEI will seek SFDA approval for the product. Terms of the agreement were not disclosed. More details...

Stock Symbol: (OTCBB: SKVI)